{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:29:40Z","timestamp":1794047380660,"version":"4.8.0"},"reference-count":50,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"10","license":[{"start":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T00:00:00Z","timestamp":1620259200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Plasmablastic lymphoma (PBL) is an aggressive B-cell lymphoma with an immunoblastic\/large-cell morphology and terminal B-cell differentiation. The differential diagnosis from Burkitt lymphoma, plasma cell myeloma and some variants of diffuse large B-cell lymphoma may be challenging because of the overlapping morphological, genetic and immunophenotypic features. Furthermore, the genomic landscape in PBL is not well known. To characterize the genetic and molecular heterogeneity of these tumors, we investigated 34 cases of PBL using an integrated approach, including fluorescence in situ hybridization, targeted sequencing of 94 B-cell lymphoma-related genes, and copy-number arrays. PBL were characterized by high genetic complexity including MYC translocations (87%), gains of 1q21.1-q44, trisomy 7, 8q23.2- q24.21, 11p13-p11.2, 11q14.2-q25, 12p and 19p13.3-p13.13, losses of 1p33, 1p31.1-p22.3, 13q and 17p13.3-p11.2, and recurrent mutations of STAT3 (37%), NRAS and TP53 (33%), MYC and EP300 (19%) and CARD11, SOCS1 and TET2 (11%). Pathway enrichment analysis suggested a cooperative action between MYC alterations and MAPK (49%) and JAK-STAT (40%) signaling pathways. Of note, Epstein-Barr virus (EBV)-negative PBL cases had higher mutational and copy-number load and more frequent TP53, CARD11 and MYC mutations, whereas EBVpositive PBL tended to have more mutations affecting the JAK-STAT pathway. In conclusion, these findings further unravel the distinctive molecular heterogeneity of PBL identifying novel molecular targets and the different genetic profile of these tumors in relation to EBV infection.<\/jats:p>","DOI":"10.3324\/haematol.2020.271957","type":"journal-article","created":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T03:58:36Z","timestamp":1620273516000},"page":"2682-2693","source":"Crossref","is-referenced-by-count":79,"title":["MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma"],"prefix":"10.3324","volume":"106","author":[{"given":"Joan Enric","family":"Ramis-Zaldivar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanca","family":"Gonzalez-Farre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Nicolae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Pack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillem","family":"Clot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferran","family":"Nadeu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Mottok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Horn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joo Y","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randy D.","family":"Gascoyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wing C.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew L.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Valera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Enjuanes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita M.","family":"Braziel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erlend B.","family":"Smeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis M.","family":"Staudt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Rosenwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"Rimsza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"German","family":"Ott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine S","family":"Jaffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itziar","family":"Salaverria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Campo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2021,5,6]]},"reference":[{"key":"30124","unstructured":"Swerdlow SH, Campo E, Harris NL. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition). 2017."},{"key":"30125","doi-asserted-by":"crossref","unstructured":"Montes-Moreno S, Gonzalez-Medina A-R, Rodriguez-Pinilla S-M. Aggressive large B-cell lymphoma with plasma cell differentiation: immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotype. Haematologica. 2010; 95(8):1342-1349.","DOI":"10.3324\/haematol.2009.016113"},{"key":"30126","doi-asserted-by":"crossref","unstructured":"Morscio J, Dierickx D, Nijs J. Clinicopathologic comparison of plasmablastic lymphoma in HIV-positive, immunocompetent, and posttransplant patients: single-center series of 25 cases and meta-analysis of 277 reported cases. Am J Surg Pathol. 2014; 38(7):875-886.","DOI":"10.1097\/PAS.0000000000000234"},{"key":"30127","doi-asserted-by":"crossref","unstructured":"Castillo JJ, Bibas M, Miranda RN. The biology and treatment of plasmablastic lymphoma. Blood. 2015; 125(15):2323-2330.","DOI":"10.1182\/blood-2014-10-567479"},{"key":"30128","doi-asserted-by":"crossref","unstructured":"Dong HY, Scadden DT, de Leval L, Tang Z, Isaacson PG, Harris NL. Plasmablastic lymphoma in HIV-positive patients: an aggressive Epstein-Barr virus-associated extra - medullary plasmacytic neoplasm. Am J Surg Pathol. 2005; 29(12):1633-1641.","DOI":"10.1097\/01.pas.0000173023.02724.1f"},{"key":"30129","doi-asserted-by":"crossref","unstructured":"Valera A, Balague O, Colomo L. IG\/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas. Am J Surg Pathol. 2010; 34(11):1686-1694.","DOI":"10.1097\/PAS.0b013e3181f3e29f"},{"key":"30130","doi-asserted-by":"crossref","unstructured":"Taddesse-Heath L, Meloni-Ehrig A, Scheerle J, Kelly JC, Jaffe ES. Plasmablastic lymphoma with MYC translocation: evidence for a common pathway in the generation of plasmablastic features. Mod Pathol. 2010; 23(7):991-999.","DOI":"10.1038\/modpathol.2010.72"},{"key":"30131","doi-asserted-by":"crossref","unstructured":"Chang C-C, Zhou X, Taylor JJ. Genomic profiling of plasmablastic lymphoma using array comparative genomic hybridization (aCGH): revealing significant overlapping genomic lesions with diffuse large B-cell lymphoma. J Hematol Oncol. 2009; 2:247.","DOI":"10.1186\/1756-8722-2-47"},{"key":"30132","doi-asserted-by":"crossref","unstructured":"Garcia-Reyero J, Martinez Magunacelaya N, Gonzalez de Villambrosia S. Genetic lesions in MYC and STAT3 drive oncogenic transcription factor overexpression in plasmablastic lymphoma. Haematologica. 2021; 106(4):1120-1128.","DOI":"10.3324\/haematol.2020.251579"},{"key":"30133","doi-asserted-by":"crossref","unstructured":"Liu Z, Filip I, Gomez K. Genomic characterization of HIV-associated plasmablastic lymphoma identifies pervasive mutations in the JAK-STAT pathway. Blood Cancer Discov. 2020; 1(1):112-125.","DOI":"10.1158\/2643-3230.BCD-20-0051"},{"key":"30134","doi-asserted-by":"crossref","unstructured":"Chapman J, Gentles AJ, Sujoy V. Gene expression analysis of plasmablastic lymphoma identifies downregulation of B-cell receptor signaling and additional unique transcriptional programs. Leukemia. 2015; 29(11):2270-2273.","DOI":"10.1038\/leu.2015.109"},{"key":"30135","doi-asserted-by":"crossref","unstructured":"Hans CP, Weisenburger DD, Greiner TC. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004; 103(1):275-282.","DOI":"10.1182\/blood-2003-05-1545"},{"key":"30136","doi-asserted-by":"crossref","unstructured":"Bea S, Zettl A, Wright G. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood. 2005; 106(9):3183-3190.","DOI":"10.1182\/blood-2005-04-1399"},{"key":"30137","doi-asserted-by":"crossref","unstructured":"Glitza IC, Lu G, Shah R. Chromosome 8q24.1\/c-MYC abnormality: a marker for high-risk myeloma. Leuk Lymphoma. 2015; 56(3):602-607.","DOI":"10.3109\/10428194.2014.924116"},{"key":"30138","doi-asserted-by":"crossref","unstructured":"Tchernonog E, Faurie P, Coppo P. Clinical characteristics and prognostic factors of plasmablastic lymphoma patients: analysis of 135 patients from the LYSA group. Ann Oncol. 2017; 28(4):843-848.","DOI":"10.1093\/annonc\/mdw684"},{"key":"30139","doi-asserted-by":"crossref","unstructured":"Castillo JJ, Winer ES, Stachurski D. Prognostic factors in chemotherapy-treated patients with HIV-associated plasmablastic lymphoma. Oncologist. 2010; 15(3):293-299.","DOI":"10.1634\/theoncologist.2009-0304"},{"key":"30140","doi-asserted-by":"crossref","unstructured":"Guerrero-Garcia TA, Mogollon RJ, Castillo JJ. Bortezomib in plasmablastic lymphoma: A glimpse of hope for a hard-to-treat disease. Leuk Res. 2017; 62:12-16.","DOI":"10.1016\/j.leukres.2017.09.020"},{"key":"30141","doi-asserted-by":"crossref","unstructured":"Nadeu F, Clot G, Delgado J. Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia. Leukemia. 2018; 32(3):645-653.","DOI":"10.1038\/leu.2017.291"},{"key":"30142","doi-asserted-by":"crossref","unstructured":"Landau DA, Tausch E, Taylor-Weiner AN. Mutations driving CLL and their evolution in progression and relapse. Nature. 2015; 526(7574):525-530.","DOI":"10.1038\/nature15395"},{"key":"30143","doi-asserted-by":"crossref","unstructured":"Scholtysik R, Kreuz M, Klapper W. Detection of genomic aberrations in molecularly defined Burkitt\u2019s lymphoma by arraybased, high resolution, single nucleotide polymorphism analysis. Haematologica. 2010; 95(12):2047-2055.","DOI":"10.3324\/haematol.2010.026831"},{"key":"30144","doi-asserted-by":"crossref","unstructured":"Karube K, Enjuanes A, Dlouhy I. Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets. Leukemia. 2018; 32(3):675-684.","DOI":"10.1038\/leu.2017.251"},{"key":"30145","doi-asserted-by":"crossref","unstructured":"Lopez-Corral L, Sarasquete ME, Bea S. SNP-based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS to myeloma status. Leukemia. 2012; 26(12):2521-2529.","DOI":"10.1038\/leu.2012.128"},{"key":"30146","doi-asserted-by":"crossref","unstructured":"Paiva B, Corchete LA, Vidriales M-B. Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance. Blood. 2016; 127(15):1896-1906.","DOI":"10.1182\/blood-2015-08-665679"},{"key":"30147","doi-asserted-by":"crossref","unstructured":"Schmitz R, Young RM, Ceribelli M. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature. 2012; 490(7418):116-120.","DOI":"10.1038\/nature11378"},{"key":"30148","doi-asserted-by":"crossref","unstructured":"Schmitz R, Wright GW, Huang DW. Genetics and pathogenesis of diffuse large Bcell lymphoma. N Engl J Med. 2018; 378(15):1396-1407.","DOI":"10.1056\/NEJMoa1801445"},{"key":"30149","doi-asserted-by":"crossref","unstructured":"Lohr JG, Stojanov P, Carter SL. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell. 2014; 25(1):91-101.","DOI":"10.1016\/j.ccr.2013.12.015"},{"key":"30150","doi-asserted-by":"crossref","unstructured":"Teoh PJ, Chung T-H, Chng PYZ, Toh SHM, Chng WJ. IL6R-STAT3-ADAR1 (P150) interplay promotes oncogenicity in multiple myeloma with 1q21 amplification. Haematologica. 2020; 105(5):1391-1404.","DOI":"10.3324\/haematol.2019.221176"},{"key":"30151","doi-asserted-by":"crossref","unstructured":"Shaughnessy J. Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma. Hematology. 2005; 10(Suppl 1):117-126.","DOI":"10.1080\/10245330512331390140"},{"key":"30152","doi-asserted-by":"crossref","unstructured":"Koskela HLM, Eldfors S, Ellonen P. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med. 2012; 366(20):1905-1913.","DOI":"10.1056\/NEJMoa1114885"},{"key":"30153","doi-asserted-by":"crossref","unstructured":"Dang CV, O\u2019donnell KA, Juopperi T. The great MYC escape in tumorigenesis. Cancer Cell. 2005; 8(3):177-178.","DOI":"10.1016\/j.ccr.2005.08.005"},{"key":"30154","doi-asserted-by":"crossref","unstructured":"Papaemmanuil E, Rapado I, Li Y. RAGmediated recombination is the predominant driver of oncogenic rearrangement in ETV6- RUNX1 acute lymphoblastic leukemia. Nat Genet. 2014; 46(2):116-125.","DOI":"10.1038\/ng.2874"},{"key":"30155","doi-asserted-by":"crossref","unstructured":"Meyer N, Penn LZ. Reflecting on 25 years with MYC. Nat Rev Cancer. 2008; 8(12):976-990.","DOI":"10.1038\/nrc2231"},{"key":"30156","doi-asserted-by":"crossref","unstructured":"Khodabakhshi AH, Morin RD, Fejes AP. Recurrent targets of aberrant somatic hypermutation in lymphoma. Oncotarget. 2012; 3(11):1308-1319.","DOI":"10.18632\/oncotarget.653"},{"key":"30157","doi-asserted-by":"crossref","unstructured":"An G, Xu Y, Shi L. Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value. Haematologica. 2014; 99(2):353-359.","DOI":"10.3324\/haematol.2013.088211"},{"key":"30158","doi-asserted-by":"crossref","unstructured":"Pasqualucci L, Compagno M, Houldsworth J. Inactivation of the PRDM1\/BLIMP1 gene in diffuse large B cell lymphoma. J Exp Med. 2006; 203(2):311-317.","DOI":"10.1084\/jem.20052204"},{"key":"30159","doi-asserted-by":"crossref","unstructured":"Hobbs GA, Der CJ, Rossman KL. RAS isoforms and mutations in cancer at a glance. J Cell Sci. 2016; 129(7):1287-1292.","DOI":"10.1242\/jcs.182873"},{"key":"30160","doi-asserted-by":"crossref","unstructured":"Noeparast A, Teugels E, Giron P. Non- V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of trametinib and dabrafenib. Oncotarget. 2017; 8(36):60094-60108.","DOI":"10.18632\/oncotarget.11635"},{"key":"30161","doi-asserted-by":"crossref","unstructured":"Kim SJ, Shin H-T, Lee H-O. Recurrent mutations of MAPK pathway genes in multiple myeloma but not in amyloid lightchain amyloidosis. Oncotarget. 2016; 7(42):68350-68359.","DOI":"10.18632\/oncotarget.12029"},{"key":"30162","doi-asserted-by":"crossref","unstructured":"Ohgami RS, Ma L, Monabati A, Zehnder JL, Arber DA. STAT3 mutations are present in aggressive B-cell lymphomas including a subset of diffuse large B-cell lymphomas with CD30 expression. Haematologica. 2014; 99(7):e105-107.","DOI":"10.3324\/haematol.2013.101543"},{"key":"30163","doi-asserted-by":"crossref","unstructured":"Valera A, Colomo L, Mart\u00ednez A. ALKpositive large B-cell lymphomas express a terminal B-cell differentiation program and activated STAT3 but lack MYC rearrangements. Mod Pathol. 2013; 26(10):1329-1337.","DOI":"10.1038\/modpathol.2013.73"},{"key":"30164","doi-asserted-by":"crossref","unstructured":"Ding BB, Yu JJ, Yu RY-L. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood. 2008; 111(3):1515-1523.","DOI":"10.1182\/blood-2007-04-087734"},{"key":"30165","doi-asserted-by":"crossref","unstructured":"van de Donk NWCJ, Lokhorst HM, Bloem AC. Growth factors and antiapoptotic signaling pathways in multiple myeloma. Leukemia. 2005; 19(12):2177-2185.","DOI":"10.1038\/sj.leu.2403970"},{"key":"30166","doi-asserted-by":"crossref","unstructured":"Brocke-Heidrich K, Kretzschmar AK, Pfeifer G. Interleukin-6-dependent gene expression profiles in multiple myeloma INA-6 cells reveal a Bcl-2 family-independent survival pathway closely associated with Stat3 activation. Blood. 2004; 103(1):242-251.","DOI":"10.1182\/blood-2003-04-1048"},{"key":"30167","doi-asserted-by":"crossref","unstructured":"Mine S, Hishima T, Suganuma A. Interleukin-6-dependent growth in a newly established plasmablastic lymphoma cell line and its therapeutic targets. Sci Rep. 2017; 7(1):10188.","DOI":"10.1038\/s41598-017-10684-5"},{"key":"30168","doi-asserted-by":"crossref","unstructured":"Grande BM, Gerhard DS, Jiang A. Genome-wide discovery of somatic coding and non-coding mutations in pediatric endemic and sporadic Burkitt lymphoma. Blood. 2019; 133(12):1313-1324.","DOI":"10.1182\/blood-2018-09-871418"},{"key":"30169","doi-asserted-by":"crossref","unstructured":"Zhou Y, Xu Z, Lin W. Comprehensive genomic profiling of EBV-positive diffuse large B-cell lymphoma and the expression and clinicopathological correlations of some related genes. Front Oncol. 2019; 9:683.","DOI":"10.3389\/fonc.2019.00683"},{"key":"30170","doi-asserted-by":"crossref","unstructured":"Menter T, Juskevicius D, Alikian M. Mutational landscape of B-cell post-transplant lymphoproliferative disorders. Br J Haematol. 2017; 178(1):48-56.","DOI":"10.1111\/bjh.14633"},{"key":"30171","doi-asserted-by":"crossref","unstructured":"Yoon H, Park S, Ju H. Integrated copy number and gene expression profiling analysis of Epstein-Barr virus-positive diffuse large B-cell lymphoma. Genes Chromosomes Cancer. 2015; 54(6):383-396.","DOI":"10.1002\/gcc.22249"},{"key":"30172","doi-asserted-by":"crossref","unstructured":"Zhu F, Wang KB, Rui L. STAT3 activation and oncogenesis in lymphoma. Cancers (Basel). 2019; 12(1):19.","DOI":"10.3390\/cancers12010019"},{"key":"30173","doi-asserted-by":"crossref","unstructured":"Lam LT, Wright G, Davis RE. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{k}B pathways in subtypes of diffuse large B-cell lymphoma. Blood. 2008; 111(7):3701-3713.","DOI":"10.1182\/blood-2007-09-111948"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2020.271957\/73352","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2020.271957\/73722","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/10260\/73352","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T09:59:33Z","timestamp":1794045573000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2020.271957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,6]]},"references-count":50,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,10,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2020.271957","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5,6]]}}}